The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Louisiana's climate fosters a variety of allergens, like pollen and mold. And as an "allergy capital," the city rarely gets ...

While allergies in domesticated animals like dogs, cats, horses, and some birds are common, experts say there are few ...

CRAIG T. KOJIMA / NOV. 6 The judge instructed jurors Wednesday that they were allowed to find babysitter Dixie Denise Villa ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product revenue for neffy sales, which reflects revenues from only one week following ...

Phenylephrine is included in many cold and flu products, but a scientific panel last year found that it doesn't really do its ...

One specific type of viral exanthem that dermatologists have seen with COVID is a morbilliform rash, meaning a measles-like ...

The arrival of spring is traditionally associated with allergies, but the crisp air brought on by autumn’s cooler weather doesn’t necessarily mean everyone can take a breath of relief.

Explore the potential of Celldex's Barzolvolimab in Phase 3 for CSU, with strong efficacy but safety concerns, promising ...